In their study, TP53 mutation was mutually exclusive from CD58 mutation in patients with DLBCL, and patients' different OS could be stratified by mutation or not in these two genes and their related differential tumor microenvironment.44 This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.